Real-world Clinical Efficacy of Abatacept in the T3 Data Registry
| Status: | Completed |
|---|---|
| Conditions: | Arthritis, Rheumatoid Arthritis |
| Therapuetic Areas: | Rheumatology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/8/2017 |
| Start Date: | March 2012 |
| End Date: | November 2016 |
Abatacept in T3: A Characterization of Abatacept's Efficacy and Outcomes From a Real-Word Clinical Practice Information Hub on Novel Patient Sub-Groups
The purpose of this study is to assess the effectiveness of Abatacept in real-world clinical
practice. The main hypothesis to be examined in this study is, "Abatacept's effectiveness
results in a single real-world clinic (n = 100) are reproducible at another site (n ~= 200)".
practice. The main hypothesis to be examined in this study is, "Abatacept's effectiveness
results in a single real-world clinic (n = 100) are reproducible at another site (n ~= 200)".
Two secondary hypotheses that will be tested are:
- Abatacept aids in achieving low disease activity or clinical remission in patients of
the following Rheumatoid Arthritis (RA) sub-groups: RF+/CCP+, RF+/CCP- RF-/CCP+
RF-/CCP-; first time on a bio-tech drug; having previously failed a biological drug;
having interstitial lung disease; identified as disabled; twenty-eight individual joints
identified as {swollen, painful, tender, deformed or having decreased range of motion};
on or not on oral DMARD; age; or gender.
- A database with sufficient attributes exists from which a patient's efficacy on
abatacept is accurately predictable.
- Abatacept aids in achieving low disease activity or clinical remission in patients of
the following Rheumatoid Arthritis (RA) sub-groups: RF+/CCP+, RF+/CCP- RF-/CCP+
RF-/CCP-; first time on a bio-tech drug; having previously failed a biological drug;
having interstitial lung disease; identified as disabled; twenty-eight individual joints
identified as {swollen, painful, tender, deformed or having decreased range of motion};
on or not on oral DMARD; age; or gender.
- A database with sufficient attributes exists from which a patient's efficacy on
abatacept is accurately predictable.
Inclusion Criteria:
- Diagnosed with rheumatoid arthritis
- Have used Abatacept for 3 or more months
Exclusion Criteria:
We found this trial at
1
site
Click here to add this to my saved trials
